worldwide. Their use in molecular US imaging applications has been hindered by their limited distribution to the vascular space. Acoustic droplet vaporization (ADV) of nanoscale superheated perfluorocarbon nanodroplets (NDs) demonstrates potential as an extravascular contrast agent that could facilitate USbased molecular theranostic applications. However these agents are metastable and difficult to manufacture with high yields. Here, we report a new formulation technique that yields reliable, narrowly dispersed sub-300 nm decafluorobutane (DFB) or octafluoropropane (OFP)-filled phospholipid-coated NDs that are stable at body temperature, using small volume microfluidization. Final droplet concentration was high for DFB and lower for OFP (>10 12 vs. >10 10 NDs per mL). Superheated ND stability was quantified using tunable resistive pulse sensing (TRPS) and dynamic light scattering (DLS).
Introduction
Owing to their increased nonlinear acoustic response compared to biological tissues, micron-scale peruorocarbon (PFC) gaslled microbubbles (MBs) have proven to be highly efficient ultrasound (US) contrast agents in many diagnostic and therapeutic applications, including echocardiography, vascular perfusion imaging, US-enhanced thrombolysis and drug/gene delivery across biological barriers such as the blood-brain barrier (BBB) and endothelium. [1] [2] [3] [4] However, their relatively large size connes them to the intravascular space. When used for molecular imaging applications, they present unique challenges as they can only seek intravascular targets, are given in miniscule quantities (10 8 -10 9 MBs) due to the extreme sensitivity of US to MBs, and when combined with a few minutes of circulation time, severely limits their ability to interact with receptors of interest. Over the past two decades, researchers have evaluated the potential of converting nanoscale droplets of liquid PFC emulsion into gas-phase MBs for diagnostic and potential therapeutic uses, [5] [6] [7] [8] [9] [10] [11] [12] [13] image-guided and high-intensity focused ultrasound (HIFU) therapy, [14] [15] [16] [17] [18] [19] drug or gene delivery, [20] [21] [22] [23] [24] [25] sonoporation 26 and DNA fragmentation. 27 This conversion induced by exposure to US, is referred to as acoustic droplet vaporization (ADV), 28, 29 with such US contrast agent referred to a phase-change contrast agent (PCCA). Nanoscale emulsions exhibit several advantages for molecular imaging over micronscale MBs. Emulsion nanodroplets (NDs) have been shown to have longer in vivo dwell times, up to 4-5 hours in the case of dodecauoropentane, 13, 30, 31 whereas MB circulation times are limited to minutes. 32 Prolonged circulation times are expected to translate to a targeting advantage of emulsions over MBs, given increased temporal and physical opportunity for ligandreceptor interaction. Emulsion NDs, up to 400 nm, are within the size regime able to extravasate into the extracellular space of tumors, with potential for nonspecic tumor targeting through the enhanced permeability and retention (EPR) effect, 33 an advantage over intravascular MBs. Emulsion NDs appear to be more resistant to US destruction than MBs, as NDs that accumulated in tumor tissue in vivo vaporized only in response to high intensity focused ultrasound, but not grayscale ultrasound. 34 By contrast, microbubbles are well known to be very susceptible to destruction by ultrasound imaging within clinically used ultrasound pressures. 35 Finally, the phase change of ADV holds potential for drug/gene delivery, and can be used to deliver a drug payload upon vaporization.
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Despite promising potential applications, certain challenges remain before successful translation and widespread use of PCCA. Specically, emulsication of low boiling point PFCs into stable NDs is difficult and the products are typically of limited shelf-life, 36, 37 prompting search for stabilizing techniques. 38 The most commonly used and favored method of producing low boiling point (<0 C) nanodroplets of liquid decauorobutane
C) begins by producing MBs using sonication or highspeed mechanical agitation of the dispersion medium with the PFC vapor present in the headspace. 36, 37, [39] [40] [41] While this approach results in successful production of PCCAs, the resulting NDs have a wide size distribution requiring ltering of the nal sample, 42 relatively low particle counts, and most importantly, a large number of $100 nm-sized likely non PFClled liposomes that are generated during MB production and condensation. In addition, spontaneous vaporization into MBs has been reported due to thermal instability of such NDs.
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These limitations can affect PCCAs behavior in vivo including circulation time, organ retention, and side effects that inu-ences in vivo applications. Microuidics has been used to generate peruoropentane droplets with a lower size limit of approximately 7 mm and very narrow size distributions; 43 however, this approach is limited to PFCs that boil above 0 C, low droplet production rates, large droplet sizes, and potential clogging of microuidic channels. To enable successful translation of PCCAs, improved emulsion formulation is needed. The objective of this study is to develop a reproducible and reliable method for manufacturing submicron-sized stable emulsions of superheated PFC with high yield and narrow size distribution. The high pressure homogenization approach proposed in this study enabled production of small and activatable DFB and OFP NDs that are stable at 37 C temperature, and undergo US-triggered phase change at clinically relevant mechanical indices. This is the rst report in which high pressure homogenization was applied to liquids with a boiling point <0 C, enabling the formulation of reproducible high quality emulsions.
Experimental section

Materials and methods
Lipids were purchased from Avanti (Alabaster, AL) and Corden Pharma (Liestal, Switzerland). DFB and OFP were purchased from F2 Chemicals Ltd (Preston, UK 
Nanodroplet formulation
A suspension of phospholipid surfactants was produced by dissolution of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-Nmethoxy(polyethyleneglycol)-2000 (DSPE-PEG2000) in a 9 : 1 molar ratio at a total lipid concentration of 3.5 mg mL À1 . The excipient solution was composed of PBS 1Â, propylene glycol and glycerol in a 16 : 3 : 1 v/v/v ratio. Dry lipid lm was dispersed in the excipient solution and heated at 70 C for 15 min followed by 15 min of sonication in a bath sonicator (Branson by Thermo Fisher Scientic, Rockford, IL) at 68 C in degassed water. The resulting sample was cooled for 2 min in a À20 C sodium chloride/ice bath ($1 to 3 ratio by weight), transferred to a 3 mL syringe and kept in the ice bath. DFB was condensed by owing DFB gas into a scintillation vial cooled at À72 C in an ethanol/dry ice bath. 150 mL of the resulting liquid DFB was added into the lipid solution and the emulsion produced through direct high pressure homogenization (9 cycles at 13 000 psi) with both coil and tray remaining cooled at À15 C using ice and sodium chloride ($1 to 3 ratio by weight). The nal emulsion was centrifuged for 2 min at 250g to remove any foam and then stored at 4 C. Specic components and operating parameters as well as illustrative photographs of the formulation process are available in the ESI ( Fig. S1 and S2 ‡). OFP NDs were prepared using the same method with the following modications. The excipient solution was composed of propylene glycol and PBS 1Â in a 6 : 4 v/v ratio. The colloidal dispersion was cooled for 3 min in a À72 C ethanol/dry ice bath prior to the addition of 100 mL liquid OFP that was condensed as was done with DFB. The LV1 coil and tray were cooled to À30 C using ice, sodium chloride, dry ice and ethanol. Illustrative photographs of the formulation process are available in the ESI (Fig. S3 ‡) . DFB NDs prepared by condensation were provided by Dr Sirsi following the procedure reported by Sheeran et al. 37 Importantly, the same lipid composition, concentration and excipient as above were used to form precursor MBs ( Fig. S4A and B ‡). In parallel, liposomes obtained with both techniques were prepared and used as control experiment (Fig. S4B ‡) . To generate those liposomes, we used the same lipid composition and excipient and used both procedures without the addition of DFB (sonication and subsequent amalgamation or high pressure homogenizer).
Preparation of DiD-labeled EpCAM-targeted DFB NDs
DiD-labeled DFB NDs were prepared by rst mixing DSPC, DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-5000] (DSPEPEG5000Mal) in a molar ratio of 9 : 0.8 : 0.2. 8 mL of a 1 mM DiD solution in ethanol was then added once the lipid suspension was clear, followed by two more min of sonication at 68 C. The emulsion was then made using the same procedure as described above. Using the technique described by G. X. Shi et al., 44 anti-Fc IgG was thiolated using Traut reagent and puried through a Zeba Spin Desalting Column. Each antibody had approximately 3 thiol groups as measured with MeasureiT™ Thiol Assay Kit. One molar equivalent of thiolated anti EpCAM antibody or non-specic IgG as control, were added to 5 Â 10 10 maleimide-terminated NDs and the mixture rotated for 1 h at room temperature on a rotating plate at 11 rpm. NDs were then washed twice by centrifugation (400g, 25 min, 4 C), incubated with one molar equivalent of anti-human CD326 antibody and washed again to remove excess antibodies.
Sample sizing
DLS analysis was performed on three different emulsion samples in triplicates (9 total measurements). For each measurement, 5 mL of emulsion was diluted in 250 mL PBS 1Â and transferred to a cuvette by micropipette. Droplet mean hydrodynamic diameter, distribution weighed by intensity and polydispersity index are reported. DLS covers a size range from 1 nm to 10 mm. Since the derived count rate is representative of the scattering intensity in the absence of attenuation, it allows meaningful comparison between samples as the attenuation effects of the light lters are normalized. Therefore, when the sample size is constant, constant derived count rate indicates stable concentration. TRPS measurements, based on the Coulter principle, were performed on three emulsion samples diluted 1000 times in PBS in duplicates (6 measurements). Aer calibration with polystyrene beads of known size acquired from the instrument manufacturer (Izon Science), captured events are counted to yield particle count at each detected size. For these measurements we used the NP300 and NP200 nanopores that cover a size range of 85 to 900 nm, an applied stretching value of 43.8 to 45.50 mm and voltage set at 0.4-0.8 mV to keep the baseline close to 130 nA. For each measurement, the sample was analyzed at two different pressures (8 and 16 mbar) and the results averaged. Each measurement was a minimum of 500 counting events collected over a minimum of 30 s. Droplet mean and mode diameters, concentration and d 90 are reported -d 90 is the size below which 90% of counted particles reside.
Sample stability
Aer preparation, samples from each of the 3 emulsions were transferred into 3 mL glass vials with no gas headspace and stored at 4 C. These emulsion samples were characterized by DLS and TRPS at the time of manufacture and then approximately every 3 days over 18 days in triplicates. Three additional emulsion samples were stored at room temperature (22 C). These samples were characterized at baseline and at 3, 27, and 50 h later. The nal three emulsion samples were heated to 37 C and characterized by DLS and TRPS over 2 h. DLS measurements were acquired at baselines and then at 5, 15, 30, 90, and 120 min. TRPS measurements were acquired at baseline, and then at 15, 30, 60, and 120 min. Potential size, distribution and concentration changes over time were recorded. DLS was also performed at baseline and at 5 and 10 min aer heating the samples to 40 C.
The sample was monitored for microbubble formation due to thermal instability (i.e., spontaneous vaporization) over 20 minutes at 37
C. An experimental setup identical to that shown in Fig. 1 was employed, but at an in situ peak negative pressure (PNP) of 0.86 (sub-threshold acoustic power) and with the same ND concentration used in the acoustic droplet vaporization evaluation.
In vitro acoustic droplet vaporization DFB ND emulsions were diluted to 1.6 Â 10 9 NDs per mL into 3 mL PBS buffer in a plastic transfer pipet bulb. The bulb was placed in a tightly tting phantom containing 0.5% corn starch acoustic scatterers in 1% agarose, and the entire assembly immersed in a heat-controlled water bath maintained at 37 C (Fig. 1) . Traditional brightness-modulated (B-mode) US imaging was performed 5 min aer sample immersion using a xed 15L8 (Fig. S5 ‡) . The in situ peak negative pressure (PNP) output by the ultrasound transducer was measured using a calibrated hydrophone whose tip was placed at the electronic focus of the ultrasound transducer, 2 cm from the transducer face, where vaporization was concentrated in all of our experiments. These measurements were performed with and without the agarose/cellulose/pipette wall in the path between the transducer and hydrophone (Fig. S6 ‡) . Samples were exposed to incremented US transmit powers from the lowest (À30 dB, onscreen MI ¼ 0.05, PNP ¼ 0.13 MPa) to the highest (0 dB, onscreen MI ¼ 1.1, PNP ¼ 2.68 MPa) while continuously capturing US images. A region-of-interest was drawn over the lumen of the bulb and mean signal intensity measured using ImageJ. 45 Experiments were done in triplicate and the mean image intensity AE standard deviation (SD) was plotted as a function of US transmit power. Vaporization threshold was dened as the power at which signal increased by >2 SD.
In vitro cell targeting
SK-BR-3 cells (5 Â 10
5
) were plated in a cell culture chamber slide (Millicell EZ SLIDES, Millipore, Billerica, MA) and 0.5 mL of McCoy's 5a medium added. Once cells were adherent, an excess of anti-human EpCAM labeled or control NDs (1 Â 10 9 )
were added and allowed to incubate at room temperature for 30 min. Cells were then washed 3 times with PBS to remove unbound NDs prior to microscopy.
Results and discussion
Nanodroplet size distributions
Manufacturing DFB emulsions using a high pressure homogenizer at À20 C yielded stable, mono-size particle emulsions with a high ND concentration (Fig. 2) . DLS intensity weighted distribution showed a single peak centered at 294 AE 20 nm that was nearly normally distributed with a 0.16 PDI and slightly skewed towards smaller particles. While DLS is not useful for measuring microbubbles or multimodal particle populations, the fact that a single nearly normally distributed peak was observed suggests the absence of microbubbles in the emulsion sample (Fig. 2) . Positive controls consisting of NDs in coexistence with various concentration of Denity MBs (1, 10 and 50%) conrmed that DLS pick up the peak associated with the MBs in addition to the NDs (Fig. S7 ‡) . The histogram ND size distribution acquired using TRPS is also shown in Fig. 2 TRPS was done with 500, 1000, 2000 and 3000 counting events (Fig. S8 ‡) and the fraction of the population with diameters greater than 500 nm was measured. While large droplets will likely contribute the most to thermal instability due to their lower Laplace pressure, they did not represent more than 0.9 AE 0.3% of the droplet count (n ¼ 3).
Currently, the preparation of NDs by condensation of MBs is being advocated. Using this technique, the concentration of NDs samples is limited to the concentration of the precursor microbubbles ($10 9 MBs per mL). While it is well known that liposomes are generated during the production of MBs, there is no comprehensive report on their concentration. However, it is essential to evaluate the fraction of the population composed of liposomes post condensation, because those small size non echogenic liposomes will contribute to the count of sub-200 nm particles in the sample, which leads to overestimation of the ND concentration in the sample (Fig. S4 ‡) . Manufacturing DFB emulsions using the condensation method yielded a low concentration of NDs (up to 2.7 Â 10 9 MBs per mL in 1 mL, (Fig. S4B ‡) . This concentration includes both NDs and liposomes with a maximal concentration of NDs of 2.7 Â 10 9 NDs per mL (100% conversion of all MBs into NDs). As a control, we formulated liposomes obtained using the same technique in the absence of DFB and obtained a concentration of 6.1 Â 10 11 liposomes per mL, which further demonstrates that in the absence of multiple washes to isolate MBs from liposomes, the majority of small particles present in the ND sample obtained by condensation is in fact liposomes. On the other hand, liposomes formulated by high pressure homogenization (Fig. S4C ‡) are sub-150 nm and do not represent a signicant portion in the ND formulation. Note that in average, a concentration of 10 12 NDs per mL was obtained for a nal volume of 3 mL using our method.
Nanodroplet emulsion stability at 4 C
Storage stability is an essential requirement for low-boiling point PFC-in-water nanoemulsions to be of practical use. Shelf-life stability was assessed with both DLS and TRPS, by monitoring ND size and concentration over 18 days of storage at 4 C. Although MBs cannot be reliably sized using DLS because their buoyancy counteracts Brownian motion, their presence affects both the size distribution and correlation graphs. No signicant change in intensity, size, derived count rate or concentration were detected over the observation period, conrming emulsion stability (Fig. 3) . DLS conrmed complete absence of mm-sized particles residing between 800 nm and 10 mm as well as the development of a multimodal distribution indicating that there are no MBs or large aggregates. No signicant uctuations were observed in intensity distribution, Y-intercept of the correlation functions, exponential decay lifetime, or emulsion characteristics from baseline values (Fig. S9 ‡) . Further, ND emulsions withstood freezing at À20 C without signicant loss of concentration (data not shown).
Nanodroplet emulsion thermal stability
In addition to shelf-life stability we also examined DFB emulsion stability at room temperature (22 C) over 50 h ( Fig. 4A and B) and at 37 C for 2 h (Fig. 4C and D) . At room temperature, 94 AE 13%, 78 AE 15% (not statistically signicant, p ¼ 0.2315, based on two-tailed paired Student's t-test) of the ND population remain aer 3 and 27 h respectively. At 
. DLS conrmed that DFB NDs exhibit optimal stability over a period of at least 2 h with no detection of particles >1 mm nor changes in size distribution (distribution weighted by intensity, volume and number) (Fig. 5A-C) , and particle derived count rate (Fig. 5D) . While no decrease in concentration nor changes in size were observed at 37 C, the ND sample showed changes in shape of the correlation curve suggestive of the appearance of microbubbles and liposomes when heated to 40 C (Fig. S10 ‡) , most likely due to the phase-transition of the largest and least thermally stable droplets. While DLS and TRPS conrmed stability by maintenance of size distribution and concentration, we also looked for a phase transition to occur using B-mode. When DFB NDs were exposed to a sub threshold acoustic power (onscreen MI ¼ 0.32, measured PNP ¼ 0.86) at 37 C, signal intensity remained at baseline without signicant vaporization (Fig. 6 ). As expected, only a very limited B-mode signal was observed during 20 minutes of incubation at 37 C (mean intensity < 10 a.u. vs. $125 a.u. for PNP at 2.68). This low signal was attributed to the small population of the largest droplets in the sample (the rightweighted tail in the distribution), less stable due to their lower Laplace pressure. B-mode is extremely sensitive and can detect a single microbubble. The lack of microbubble formation on Bmode over 20 minutes at 37 C with a sub-threshold MI conrmed the thermal stability observed with DLS and TRPS.
Nanodroplet vaporization in vitro at 37 C As DFB requires more transmitted acoustic energy to vaporize in vivo than it does in vitro due to greater US attenuation by tissues, we also made emulsions of OFP that has a lower boiling point (À36.7 C) than DFB (À1.7 C) and should require less energy to vaporize (Fig. S11 ‡) . DLS intensity data of OFP emulsions demonstrated a single peak centered at 203 AE 13 nm that was normally distributed with a 0.3 PDI. The OFP size distribution by TRPS was slightly skewed to the le with a mean diameter of When OFP and DFB NDs were exposed to increasing acoustic power at 37 C, signal intensity remained at baseline without vaporization until the PNP passed 0.38 for OFP and 1.07 for DFB (Fig. 7) . Also note that while vaporization of DFB was gradual with increasing PNP, OFP signal reached a plateau at a PNP >0.8. As expected, these results conrm that PFC boiling point inuences NDs vaporization threshold. NDs obtained by the condensation method only presented a low vaporization signal at an identical concentration, which is in agreement with our hypothesis that the majority of small particles present in the ND sample is non echogenic liposomes and not NDs.
Nanodroplet functionalization, purication and in vitro targeting
A key advantage of ND formulations is their greater opportunity to target receptors in vivo compared to MBs because of their smaller size, larger particle count and longer circulation time.
The challenge of producing targeted ND of low boiling point PFCs, is the additional time and manipulation required to attach and then wash excess ligands. We attached anti-EpCAM or non-specic IgG antibodies to DiD-labeled DFB NDs and showed by uorescence microscopy that targeted but not control NDs bound to EpCAM positive SK-BR-3 cells (Fig. 8 ).
An ideal PCCA formulation should produce NDs with a vaporization threshold achievable by diagnostic clinical ultrasound systems combined with an optimal thermal stability at room and physiological temperatures to allow for practical handling and performance. The formulation and emulsication technique presented here resulted in several unique properties to achieve this goal including: (1) sub-300 nm DFB NDs with narrow size distribution (PDI < 0.2); (2) absence of MBs; (3) high ND concentration (>10 12 NDs per mL); (4) high stability over 3 weeks at 4 C, and over 27 h at room temperature; and more importantly, over 2 h at physiological temperature (37 C) without measurable decrease in ND concentration. In contrast, DFB NDs made with the condensation method were reported to be unstable at 4 C aer 5 h. 37 Further, the condensation method resulted in droplets with a broad particle size 7 NDs per mL OFP as a function of peak negative pressure (PNP). Representative US images and mean image intensity are shown as well as photographs of the transfer pipet bulb containing DFB NDs before and after US exposure (direct). Change in sample opacity is a hallmark feature of PCCA activation. "Direct" and "condensation" refer to the direct formulation of NDs by high pressure microfluidization and condensation of preformed MBs into NDs respectively. distribution, and low particle concentration. 37 Although the count is likely dependent on the initial MBs concentration, we speculate that the condensation method likely produces a larger number of non-PFC containing liposomes, although this possibility was not discussed or reported.
Another important distinction is that neither DFB nor OFP NDs vaporized at physiological temperature until they were exposed to ultrasound at clinically relevant power ($0.4 MI for DFB, and $0.14 MI for OFP). As expected, when the NDs phase transitioned to MBs they produced a high contrast-to-noise ratio on B-mode US imaging.
A key element of the direct emulsication technique is that the resultant NDs are stable to allow further processing to produce labeled and functionalized systems, allowing the removal of non-PFC containing liposomes as well as unbound small molecules or antibodies. This purication capability assures optimal purity and paves the way for use of targeted NDs for molecular US-based theranostics. The in vitro results conrmed that NDs produced by direct emulsication and subsequent functionalization are able to target their intended receptors.
Conclusions
This work conrms that direct emulsication of low boiling point PFC into liquid nanodroplets for phase-shi ultrasound controlled vaporization is possible. Emulsions of DFB were stable for >18 days (entire observation periods) at 4 C and >1
day at room temperature allowing further processing for functionalization and purication. More important, DFB formulations were stable for at least 2 h at physiologic temperature without spontaneous vaporization, allowing ample time for targeting and tissue accumulation. They transitioned into MBs in vitro only when exposed to ultrasound at low PNP (0.38 for OFP and 1.07 for DFB) producing marked enhancement on Bmode US imaging. We believe that these results will accelerate in vivo testing and translation of these promising US contrast agents.
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